7 July 2020
Dr Karen Street, Assistant Officer for Mental Health and Wellbeing, responds to a new BMA report which considers the impact of COVID-19 on mental health.
26 June 2020
Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019, because of fears that they may contain low levels of an impurity called NMDA.
16 June 2020
Changes have been made to our Child Protection Companion's chapter 9, ''Recognition of physical abuse' to accommodate suggested amendments by the British Paediatric and Adolescent Bone Group on the timing of blood investigations for fractures.
17 March 2020
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
Surveillance of outcome of resuscitated term babies with no heart rate detected at 10 minutes of age starts next month
5 March 2020
This study, run through the British Paediatric Surveillance Unit (BPSU), will identify the incidence of term babies who receive resuscitation following birth and have no heart rate detected at 10 minutes of age, describing the demographic characteristics, clinical features and initial management of ...
4 March 2020
The RCPCH has today published State of Child Health 2020, the largest ever compilation of data on the health of babies, children and young people across all four UK nations. The report shows that for many measures of children’s health and wellbeing, progress has stalled, or is in reverse – something...
2 March 2020
The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.
5 February 2020
Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.
31 January 2020
The review was commissioned by the Chief Executive of NHS England to assist its Board in the evaluation of responses to a consultation undertaken in summer 2019 relating to a new draft service specification for children’s cancers.
16 December 2019
Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg because of a lack of evidence for benefit.